Top Markets
#1 ONFA ONFA +225.76%
#2 Resolv wstUSR Resolv wstUSR +198.02%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +38.13%
#6 NKN NKN +36.26%
#7 StakeStone StakeStone +28.59%
#8 BLOCKv BLOCKv +26.08%
#9 KONET KONET +24.91%
#10 OpenVPP OpenVPP +22.33%
Coin of the day
ONFA ONFA
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classement en actions #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Prix de l'action
$0.5275
Capitalisation boursière
$1.25M
Changement (1 jour)
-3.56%
Changement (1 an)
-83.77%
Pays
US
Échange Ensysce Biosciences, Inc. (ENSC)

Catégorie

Healthcare
Revenus pour Ensysce Biosciences, Inc. (ENSC)
Revenus en Sep 2025 TTM : $4.49M
Selon les derniers rapports financiers de Ensysce Biosciences, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $4.49M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $2.23M une diminution par rapport à le chiffre d'affaires de l'année 2022, qui était de $2.52M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Ensysce Biosciences, Inc. de 2017 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $4.49M -13.85%
2024 $5.21M 133.53%
2023 $2.23M -11.59%
2022 $2.52M -28.54%
2021 $3.53M -10.18%
2020 $3.93M 122.86%
2019 $1.76M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 1,079,095.70%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 268,123.28%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 319,469.02%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 202,258.79%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 349,599.93%
AU